Equillium Profile

Performance

   

Odds of Distress

Check how we calculate scores
Equity ratings for Equillium are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 19, 2019 and ending today September 17, 2019. Click here to learn more.
3.81
USD 0.27  6.62%

Equillium Summary

Equillium (EQ) is traded on BATS Exchange in USA. It is located in 2223 Avenida De La Playa and employs 16 people. Equillium is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with market capitalization of 68.72M. Equillium is active under Healthcare sector as part of Biotechnology industry. The entity has 17.38M outstanding shares of which 138.45K shares are currently sold short in the market by investors with about 3.77 days to cover all shorted shares. EMBARQ CORP reports about 56.94M in cash with (14.69M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.28.
Check Equillium Probability Of Bankruptcy

Ownership Allocation (%)

Equillium Target Price Odds Analysis

Odds Below 3.81HorizonTargetOdds Above 3.81
18.65%30 days 3.81 81.29%
Based on normal probability distribution, the odds of Equillium to move above current price in 30 days from now is about 81.29% (This Equillium probability density function shows the probability of Equillium Stock to fall within a particular range of prices over 30 days) .

Equillium Top Holders

Equillium Risk Profiles

Equillium Key Fundamentals

Equillium Against Markets

Equillium Vital Trading Data

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California. Equillium operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 16 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Equillium SEC Filings
Equillium SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameEquillium
President CEO, DirectorGeoffrey RotsteinView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationCalifornia U.S.A
Business Address2223 Avenida De La Playa
Foreign Associate  Canada
ExchangeBATS Exchange
CUSIP29446K106
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.equilliumbio.com
Phone858 412 5302
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestAugust 15, 2019

Equillium Corporate Directors

John Fisher Independent Director
Anthony Tjan Independent Director
Marc Lavine Independent Director
Additionally see Investing Opportunities. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Search macroaxis.com